Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Bile Duct Patency After Photodynamic Therapy in Unresectable Cholangiocarcinoma
NCT04860154Completed
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
- Start
- Apr 2021
- Primary completion
- Nov 2024
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Open-label trial of hemoporfin in cholangiocarcinoma (CCA) (2 arms), sponsored by Hepatopancreatobiliary Surgery Institute of Gansu Province. Primary endpoints: Bile duct patency at 3 years and Median survival time at 3 years. Started Apr 2021; status: completed.
02
Drugs
hemoporfin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04860154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04860154.